Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills
  1. Research Outputs

Nanoemulsions of cannabidiol, Δ9-tetrahydrocannabinol, and their combination similarly exerted anticonvulsant and antioxidant effects in mice treated with pentylenetetrazole

Academic Article
Publication Date:
2025
Short description:
Nanoemulsions of cannabidiol, Δ9-tetrahydrocannabinol, and their combination similarly exerted anticonvulsant and antioxidant effects in mice treated with pentylenetetrazole / Everson Alexandre De Aquino, Pedro; Josimar Girão Júnior, Francisco; De Souza Nascimento, Tyciane; Rosal Lustosa, Ítalo; Matos De Andrade, Geanne; Maria Pontes Silva Ricardo, Nágila; Hellen Almeida De Brito, Débora; Érik Patrício De Almeida, Gabriel; Barreto Silveira, Kamilla; Zampieri, Davila; Maria De França Fonteles, Marta; Rocha Silveira, Edilberto; Biagini, Giuseppe; Socorro De Barros Viana, Glauce. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 18:6(2025), pp. 1-31. [10.3390/ph18060782]
abstract:
Background/Objectives: The main biologically active molecules of Cannabis sativa L. are cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). Both exert anticonvulsant effects when evaluated as single drugs, but their possible interaction as components of C. sativa extracts has been scarcely studied. For this reason, we evaluated CBD and THC, combined or not, in two seizure models in mice, using an improved vehicle formula. Methods: Firstly, acute seizures were induced by intraperitoneal (i.p.) pentylenetetrazole (PTZ, 80 mg/kg), and mice received CBD or THC at 1, 3, 6, and 10 mg/kg, or a CBD/THC 1:1 combination at 1.5, 3, and 6 mg/kg, per os (p.o.), one hour before PTZ administration. Secondly, mice received p.o. CBD (10 mg/kg), CBD/THC (1.5, 3, and 6 mg/kg), valproic acid (50 mg/kg), or vehicle (nanoemulsions without CBD or THC), one hour before PTZ (30 mg/kg, i.p.) every other day for 21 days. Behavioral, biochemical, and immunohistochemical analyses were performed to assess the response to PTZ, oxidative stress, and astroglial activation. Results: In the acute model, CBD and THC at 3-10 mg/kg, and their combinations, significantly increased latency to generalized seizures and death, and improved survival rates. In the chronic model, similarly to valproic acid, CBD 10 mg/kg and CBD/THC at 1.5 and 3 mg/kg delayed kindling acquisition, while CBD/THC 6 mg/kg had no effect. CBD and CBD/THC treatments reduced oxidative and nitrosative stress and attenuated astrogliosis, as indicated by decreased glial fibrillary acidic protein and GABA transporter 1 expression and increased inwardly rectifying potassium channel 4.1 expression in hippocampal regions. However, no cannabinoid treatment prevented the impairment in novel object recognition and Y maze tests. Conclusions: These findings support the potential role of cannabinoids in counteracting seizures, possibly by reducing oxidative stress and astrogliosis. The study also highlights the importance of nanoemulsions as a delivery vehicle to enhance cannabinoid effectiveness while considering the risks associated with direct cannabinoid receptor activation.
Iris type:
Articolo su rivista
Keywords:
cannabidiol; epilepsy; nanoemulsion; pentylenetetrazole; Δ9-tetrahydrocannabinol
List of contributors:
Everson Alexandre De Aquino, Pedro; Josimar Girão Júnior, Francisco; De Souza Nascimento, Tyciane; Rosal Lustosa, Ítalo; Matos De Andrade, Geanne; Maria Pontes Silva Ricardo, Nágila; Hellen Almeida De Brito, Débora; Érik Patrício De Almeida, Gabriel; Barreto Silveira, Kamilla; Zampieri, Davila; Maria De França Fonteles, Marta; Rocha Silveira, Edilberto; Biagini, Giuseppe; Socorro De Barros Viana, Glauce
Authors of the University:
BIAGINI Giuseppe
Handle:
https://iris.unimore.it/handle/11380/1378528
Full Text:
https://iris.unimore.it//retrieve/handle/11380/1378528/925746/pharmaceuticals-18-00782-v3.pdf
Published in:
PHARMACEUTICALS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.4.5.0